DCVax-L: Personalized Vaccine, Glioblastoma, Braelyn Hollensbe, One Clear Scan and A Broken Access Path (2026)

Last updated: September 18, 2026. Based on public updates from Braelyn’s family and published DCVax-L trial papers. Not medical advice. One patient’s scan is not a clinical trial.

On September 15, 2026, Amanda Hollensbe posted the sentence she said she had waited almost three years to write: no evidence of disease. (1)

Her daughter, Braelyn, was diagnosed with glioblastoma after turning 16. She is now a young adult in college, traveling from South Carolina to London for a personalized dendritic cell vaccine called DCVax-L. UCLA neurosurgeon Dr. Linda Liau and the UCLA tumor board reviewed an August 28 MRI and told the family the remaining tumor left at surgery was no longer visible.

That is extraordinary news in GBM. It is also an access story. The family reached Liau through a stranger on X. The vaccine being given in London was developed in the United States. The tissue that made the vaccine possible had to be preserved the right way at surgery. None of those steps are standard for a newly diagnosed teenager.

What is public so far: local radiology first called the August 28 scan free of recurrence. UCLA then confirmed no visible tumor, including the roughly 10% residual Liau had to leave because it involved critical brain structures. The family says Braelyn has received three DCVax induction doses plus a first booster, recently started Keytruda (pembrolizumab), and was told to keep the current plan. NED on MRI is not the same as cured.

Why this case is larger than one MRI

GBM is still one of the hardest adult cancers to treat. Median survival with surgery, radiation, and temozolomide is about 15 to 17 months. Five-year survival is typically near 5%. Braelyn’s tumor is MGMT-unmethylated, the group that usually gets little benefit from temozolomide.

Her mother’s public timeline is specific:

• The tumor later became enormous and grew across three lobes.
• Multiple surgeons, including at major centers, declined further surgery as too risky.
• The offered path was more chemotherapy and photon radiation that would affect a large volume of brain.
• An X connection with long-term GBM survivor Thomas Owen McCarthy led the family to Liau.
• Liau operated, removed about 90% of the mass, and stopped where more resection would threaten critical structures.
• This time the tumor tissue was properly preserved and sent to England to manufacture DCVax-L.
• Treatment continues in London under a special-access pathway, with additional doses planned into 2029.

Amanda’s argument is not only “the vaccine worked.” It is that families should not have to assemble a potentially life-extending sequence by accident: a willing surgeon, correct tissue handling, an investigational product, and the money to fly to another country for years.

The treatment stack behind one “NED” report

It is tempting to assign the scan to a single drug. The public record does not support that shortcut. Braelyn’s recent course includes:

1. Maximal safe resection by a high-volume glioma surgeon
2. Radiation, including the family’s earlier choice of proton therapy to limit off-target damage
3. Personalized DCVax-L manufactured from her own tumor lysate
4. Pembrolizumab, a PD-1 checkpoint inhibitor, started more recently

Any of those pieces, or the combination, could explain a disappearing residual on MRI. UCLA’s published research has separately studied dendritic-cell vaccination plus PD-1 blockade, because a vaccine may bring T cells into the tumor while a checkpoint drug keeps those T cells from shutting down. That is biologically coherent. It is not the same as a controlled trial in this one patient.

NED also has a narrow meaning. It means no tumor the scan can see. GBM cells can remain below the resolution of MRI. The next scans matter as much as this one.

What the DCVax-L trials actually showed

DCVax-L is an autologous vaccine: a patient’s dendritic cells are loaded with that patient’s tumor lysate and injected in the arm. The pivotal study is NCT00045968, published in JAMA Oncology in 2022 by Liau and colleagues. For the full number-by-number breakdown, see our companion explainer on DCVax-L Phase 3 survival results.

The short version:

Group	DCVax-L	External controls
Newly diagnosed median OS from randomization	19.3 months (22.4 from surgery)	16.5 months
Newly diagnosed 5-year OS	13.0%	5.7%
Recurrent median OS from relapse	13.2 months	7.8 months
MGMT methylated, newly diagnosed	30.2 months from randomization	21.3 months

The original randomized design used a 2:1 split, 232 patients to vaccine and 99 to placebo, after surgery and chemoradiation. Crossover after recurrence meant almost 90% of the trial eventually received DCVax-L. That is why the published OS comparison used external controls from other trials, not a clean internal placebo OS curve.

Two facts have to sit next to each other:

• OS versus those external controls was statistically significant (HR 0.80 newly diagnosed; HR 0.58 recurrent).
• The original primary endpoint, progression-free survival, was not better: 6.2 months with vaccine vs 7.6 months with placebo.

In July 2026, company-sponsored analyses using individual patient data from three other newly diagnosed GBM trials estimated a larger median OS advantage, about 3.4 to 6.3 months, after tighter matching. That strengthens the OS case. It does not turn one teenager’s MRI into Phase 3 proof, and it does not make DCVax-L an FDA-approved standard.

Safety in the trial was relatively clean: five serious events judged at least possibly related across more than 2,100 doses, mostly edema, plus expected injection-site and flu-like effects.

MGMT status is the hardest bridge to this case. Braelyn is unmethylated. In the 2018 look at the whole trial population, unmethylated patients still had a median OS of 19.8 months from surgery and 11% three-year survival. Methylated patients did much better. An unmethylated patient can have an excellent scan. The published median says that is not the typical path.

The access failures her family is pointing to

The policy claims in Amanda’s post are more testable than a miracle narrative. They map onto real bottlenecks.

1. Surgery is not evenly offered

Liau’s first reported reaction was that the girl needed surgery right away. Other centers had already said further surgery was too risky. In GBM, extent of safe resection is one of the few things that consistently moves survival. “Too risky” can be correct. It can also mean “not at this hospital.” Families rarely hear that distinction in time.

2. Tissue is thrown away or stored wrong

DCVax-L cannot be manufactured without usable autologous tumor lysate. In the Phase 3 program, insufficient tumor lysate excluded a slice of otherwise eligible patients. If a first or second operation happens before anyone mentions personalized immunotherapy, the option can disappear in the pathology lab. Telling families about preservation before surgery is a process change, not a speculative therapy.

3. Investigational options stay invisible at the first consult

Standard counseling after a grim GBM diagnosis is often surgery, radiation, temozolomide, and a short list of local trials. Dendritic-cell vaccines, long-term survivor clinics, and overseas special-access routes are usually found later, if at all. That is how a stranger on X became a referral network.

4. Geography and money decide who continues

The science was developed at UCLA. Braelyn receives the product in London, with travel and manufacturing costs stretching years. Public fundraisers list remaining doses into 2029. A therapy can be “available somewhere” and still unreachable for a family in South Carolina without a second job in logistics and fundraising.

As of July 2026, the UK MHRA said Northwest Biotherapeutics’ marketing application for DCVax-L was still under review and had not been refused. Until a regulator licenses it and payers cover it, special access will keep looking like a scavenger hunt.

How to hold hope and evidence at the same time

Braelyn’s scan is a genuine good day in a disease that offers few of them. College, returning hair, improving speech, and a clean MRI are not marketing copy. They are a young woman getting time back.

The honest frame is narrower than the internet will want:

• This is one well-documented case after aggressive surgery plus radiation plus DCVax-L plus a PD-1 drug.
• The Phase 3 OS data are consistent with a modest median gain and a real minority tail, not a transformation of GBM into a curable cancer.
• The access critique stands even if a reader remains skeptical of the vaccine’s effect size. Second opinions, tissue handling, and transparent talk about investigational options do not require anyone to overclaim the trial.

GBM is defined by the next scan. NED today is the result her family asked for. Durability is the result the disease has not yet given.

Questions families can ask before the first or next surgery

1. If more of this tumor can be removed safely, who is the surgeon most likely to do it?
2. Will tumor tissue be preserved in a way that keeps personalized vaccines or other autologous products possible?
3. What is the MGMT status, and how does that change the expected benefit of temozolomide?
4. Which immunotherapy or vaccine trials are open now, and what is the enrollment window after radiation?
5. If a promising product is only available outside the local system, who helps with compassionate use, travel, and cost?

FAQ

Did DCVax-L make Braelyn tumor-free?

Nobody can say that from a public post. UCLA reported no visible tumor after surgery, radiation, DCVax-L, and recently started Keytruda. That is a combination result, and MRI cannot rule out microscopic disease.

Is DCVax-L proven in glioblastoma?

The Phase 3 study showed longer OS versus external controls and failed its original PFS endpoint. It is not FDA-approved. See the companion trial-data article for tables and caveats.

Why is she treated in London if the research started at UCLA?

The product is not a routine U.S. standard therapy. The family has used a UK special-access route at King’s College Hospital while a UK regulatory review continues.

What should readers take from her story?

Ask about second surgical opinions and tissue preservation early. Treat one NED scan as hope with a follow-up date, not as proof that every GBM patient will get the same result.

---

This article does not reprint private medical records and does not recommend a treatment.

Public sources: 

1. Amanda Hollensbe post on X (Sep 2026)
2. Liau et al. in JAMA Oncology (2022) and Journal of Translational Medicine (2018), 
3. NCT00045968, 
4. Northwest Biotherapeutics BNOS 2026 update
5. July 2026 MHRA status statement.